Ixekizumab in the treatment of psoriatic arthritis

Immunotherapy. 2021 Jan;13(1):19-33. doi: 10.2217/imt-2020-0225. Epub 2020 Nov 9.


Psoriatic arthritis (PsA) is a heterogeneous chronic rheumatic disorder with numerous phenotypic facets. A better in deep understanding of the pathophysiologic mechanisms leading to psoriasis and PsA has contributed to the introduction of novel therapeutic agents. IL-17 is at the heart and a critical factor in the onset of PsA. Ixekizumab, a high-affinity monoclonal antibody against IL-17 A, has been approved by the US FDA in March 2016 for baseline psoriasis and Dec 2017 for PsA; by the EMA in April 2016 and January 2018, respectively. This article reviews the published data relating to ixekizumab efficacy and safety in the PsA treatment.

Keywords: IL-17A antagonist; biologic DMARD; ixekizumab; psoriasis; psoriatic arthritis; spondyloarthritis.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Arthritis, Psoriatic / drug therapy*
  • Dermatologic Agents / therapeutic use*
  • Humans
  • Severity of Illness Index
  • Treatment Outcome


  • Antibodies, Monoclonal, Humanized
  • Dermatologic Agents
  • ixekizumab